Show simple item record

dc.date.accessioned2019-11-06T13:54:43Z
dc.date.accessioned2019-11-22T14:14:31Z
dc.date.available2019-11-06T13:54:43Z
dc.date.available2019-11-22T14:14:31Z
dc.date.issued2018-08
dc.identifier.citationKhan J, Bashir S, Khan MA et al (2018) Fabrication and characterization of dexibuprofen nanocrystals using microchannel fluidic reactor. Drug Design, Development and Therapy. 2018(12): 2617-2626.
dc.identifier.urihttp://hdl.handle.net/10454/17494
dc.descriptionYes
dc.description.abstractPurpose: Dexibuprofen is an enantiomer of ibuprofen with low bioavailability which results from its hydrophobic nature. Nanosuspensions have developed a podium to solve the in vitro dissolution problem that frequently occurs in current research. Materials and methods: The drug and polymer solutions were mixed in a microchannel fluid reactor and the successive embryonic nanosuspension was decanted into a vial having the polymer solution. The impact of different process and formulation parameters including inlet angle, antisolvent and solvent flow rate(s), mixing time, drug concentration, polymer type and concentration was evaluated. Results and discussion: Stable dexibuprofen nanocrystals with a particle size of 45±3.0 nm and polydispersity index of 0.19±0.06 were obtained. Differential scanning calorimetry and powder X-ray diffraction confirmed the crystallinity. The key parameters observed were inlet angle 10°, antisolvent to solvent volume of 2.0/0.5 mL/min, 60 minutes mixing with 5 minutes sonication, Poloxamer-407 with a concentration of 0.5% w/v and drug concentration (5 mg/mm). The 60-day stability studies revealed that the nanocrystals were stable at 4°C and 25°C. The scanning electron microscopy and transmission electron microscopy images showed crystalline morphology with a homogeneous distribution. Conclusion: Stable dexibuprofen nanocrystals with retentive distinctive characteristics and having marked dissolution rate compared to raw and marketed formulations were efficiently fabricated. In future perspectives, these nanocrystals could be converted to solid dosage form and the process can be industrialized by chemical engineering approach
dc.language.isoen
dc.rights© 2018 Khan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
dc.subjectNanocrystal
dc.subjectDexibuprofen
dc.subjectMicrochannel fluidic reactor
dc.subjectProcess and formulation parameters
dc.titleFabrication and characterization of dexibuprofen nanocrystals using microchannel fluidic reactor
dc.status.refereedYes
dc.date.Accepted07/06/2018
dc.date.application29/08/2018
dc.typeArticle
dc.type.versionPublished version
dc.identifier.doihttps://doi.org/10.2147/DDDT.S168522
dc.rights.licenseCC-BY-NC
dc.date.updated2019-11-06T13:54:46Z
refterms.dateFOA2019-11-22T14:15:06Z
dc.openaccess.statusopenAccess


Item file(s)

Thumbnail
Name:
dddt-12-2617.pdf
Size:
1.396Mb
Format:
PDF
Description:
Isreb_et_al_DDDT

This item appears in the following Collection(s)

Show simple item record